Article
PDE-5 inhibitor use shows no effect on BPH therapy outcomes
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Sacral neuromodulation device empowers patients with greater UUI control
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Study: Women with SCI are more likely to use indwelling catheters
Discover the Art and Science Behind Nerve Sparing Prostate Surgery
Ziho Lee, MD, previews 2025 Northwestern GU robotic reconstruction course
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
Vikram Narayran, MD, on tech-driven changes that are enhancing patient care
Justin Dubin, MD, on leveraging digital tools to improve patient buy-in
Related Content
